![Flow Cytometry: Siglec-2/CD22 Antibody (hL22 (Epratuzumab)) - Chimeric [NBP2-75189] - Flow-cytometry using anti-CD22 antibody Epratuzumab. Rhesus monkey lymphocytes were stained with an isotype control (NBP2-52636, panel A) or the rabbit-chimeric version of Epratuzumab (NBP2-75189, panel B) at a concentration of 1 ug/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody and cells analysed on a FACSCanto flow-cytometer.](http://images.novusbio.com/fullsize/Siglec-2-CD22-Antibody-hL22-Epratuzumab-Chimeric-Flow-Cytometry-NBP2-75189-img0003.jpg "Flow Cytometry: Siglec-2/CD22 Antibody (hL22 (Epratuzumab)) - Chimeric [NBP2-75189] - Flow-cytometry using anti-CD22 antibody Epratuzumab. Rhesus monkey lymphocytes were stained with an isotype control (NBP2-52636, panel A) or the rabbit-chimeric version of Epratuzumab (NBP2-75189, panel B) at a concentration of 1 ug/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody and cells analysed on a FACSCanto flow-cytometer.")
| Reactivity | Hu, Pm-Cm, RMSpecies Glossary |
| Applications | Flow, IP, B/N |
| Clone | hL22 (Epratuzumab) |
| Clonality | Monoclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Format | Azide and BSA Free |
| Concentration | 1 mg/ml |
| Additional Information | Recombinant Monoclonal Antibody. |
| Immunogen | This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010). |
| Specificity | This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. |
| Isotype | IgG Kappa |
| Clonality | Monoclonal |
| Host | Rabbit |
| Gene | CD22 |
| Purity | Protein A purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
| Application Notes | This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
| Storage | Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C. |
| Buffer | PBS |
| Preservative | 0.02% Proclin 300 |
| Concentration | 1 mg/ml |
| Purity | Protein A purified |
Secondary Antibodies |
Isotype Controls |
Research Areas for Siglec-2/CD22 Antibody (NBP2-75189)Find related products by research area.
|
|
Antigen-loss relapse after successful CAR-T therapy; What do we do now? By Jacqueline Carrico, BS, MD Tumor cell mechanisms driving tolerance to CAR-T Despite very promising results of CAR-T therapy in acute lymphoblastic leukemia, B-ALL, antigen-loss relapse has arisen as a major chall... Read full blog post. |
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
| Gene Symbol | CD22 |
![Flow Cytometry: Siglec-2/CD22 Antibody (hL22 (Epratuzumab)) - Chimeric [NBP2-75189] - Flow-cytometry using anti-CD22 antibody Epratuzumab. Human lymphocytes were stained with an isotype control (panel A) or the rabbit-chimeric version of Eptratuzumab (NBP2-75189, panel B) at a concentration of 1 ug/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody and cells analysed on a FACSCanto flow-cytometer.](http://images.novusbio.com/fullsize/Siglec-2-CD22-Antibody-hL22-Epratuzumab-Chimeric-Flow-Cytometry-NBP2-75189-img0001.jpg "Flow Cytometry: Siglec-2/CD22 Antibody (hL22 (Epratuzumab)) - Chimeric [NBP2-75189] - Flow-cytometry using anti-CD22 antibody Epratuzumab. Human lymphocytes were stained with an isotype control (panel A) or the rabbit-chimeric version of Eptratuzumab (NBP2-75189, panel B) at a concentration of 1 ug/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody and cells analysed on a FACSCanto flow-cytometer.")
![Flow Cytometry: Siglec-2/CD22 Antibody (hL22 (Epratuzumab)) - Chimeric [NBP2-75189] - Flow-cytometry using anti-CD22 antibody Epratuzumab. Cynomolgus monkey lymphocytes were stained with an isotype control (NBP2-52636, panel A) or the rabbit-chimeric version of Epratuzumab (NBP2-75189, panel B) at a concentration of 1 ug/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody and cells analysed on a FACSCanto flow-cytometer.](http://images.novusbio.com/fullsize/Siglec-2-CD22-Antibody-hL22-Epratuzumab-Chimeric-Flow-Cytometry-NBP2-75189-img0002.jpg "Flow Cytometry: Siglec-2/CD22 Antibody (hL22 (Epratuzumab)) - Chimeric [NBP2-75189] - Flow-cytometry using anti-CD22 antibody Epratuzumab. Cynomolgus monkey lymphocytes were stained with an isotype control (NBP2-52636, panel A) or the rabbit-chimeric version of Epratuzumab (NBP2-75189, panel B) at a concentration of 1 ug/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody and cells analysed on a FACSCanto flow-cytometer.")
![Bioactivity CTLA-4 [Unconjugated]](https://images.novusbio.com/images2/CTLA4_7268CT_2293.jpg)
![Immunohistochemistry Neprilysin/CD10 Antibody [Unconjugated]](https://images.novusbio.com/images2/Neprilysin_AF1126_Immunohistochemistry_6679.jpg)
![Western Blot Neprilysin/CD10 Antibody [Unconjugated]](https://images.novusbio.com/images/af1126_mouse-neprilysin-affinity-purified-polyclonal-ab-8220249505976.jpg)
![Western Blot Neprilysin/CD10 Antibody [Unconjugated]](https://images.novusbio.com/images/af1126_mouse-neprilysin-affinity-purified-polyclonal-ab-44202415433122.jpg)
![Immunohistochemistry CD45 Antibody [Unconjugated]](https://images.novusbio.com/images2/CD45_AF114_Immunohistochemistry_23525.jpg)
![Immunocytochemistry CD45 Antibody [Unconjugated]](https://images.novusbio.com/images2/af114_mouse-cd45-affinity-purified-polyclonal-ab-immunocytochemistry-6122021145449.jpg)
![Immunocytochemistry/ Immunofluorescence CD45 Antibody [Unconjugated]](https://images.novusbio.com/images/af114_mouse-cd45-affinity-purified-polyclonal-ab-41202410331954.jpg)
![Immunocytochemistry CD23/Fc epsilon RII Antibody [Unconjugated]](https://images.novusbio.com/images2/CD23_AF123_Immunocytochemistry_6469.jpg)
![N/A CD25/IL-2R alpha [HRP]](https://images.novusbio.com/images2/IL-2_R_alpha_DR2A00_ELISA_167.jpg)
![N/A CD25/IL-2R alpha [HRP]](https://images.novusbio.com/images2/DATA_CD25_DR2A00_ELISA_800.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
